Lunch And Learn With Dr. Berry

In today's episode of Real Doctor Reacts, we dive into the revealing and controversial pricing strategy of Pfizer’s COVID-19 antiviral treatment, Paxlovid. Pfizer has unveiled a nearly $1,400 price tag for a five-day course of this crucial antiviral, ushering in a series of questions and debates regarding pharmaceutical practices, accessibility, and the business dynamics in play during a global pandemic. Please SUBSCRIBE for new videos every Monday afternoon and Thursday Evening https://www.drberrypierre.com/YTsubscription​ Let's Connect: Instagram TikTok Lunch and Learn Patreon Family Key Discussion Points: Business as Usual for Pharmaceutical Companies: A Critical Look at Pfizer’s Approach, aligning it within broader pharmaceutical industry trends and assessing whether this move echoes conventional profit-driven tactics. The New Pricing Structure: What's the Timeline?: Unraveling when this new pricing will be instituted, and the anticipated immediate effects on the access and distribution of the antiviral.